|
KOREA LAB Autumn
|
KORINSTECH
|
Gel Hardness Tester, Tablet Hardness Tester, Leak Tester, Micro Leak Tester
|
F12
|
|
PARTNERING
|
Liberi-CCubeLab Inc.
|
Liberi-CCubeLab is a global licensing & BD consulting firm specializing in the pharmaceutical and bio sectors. It is a joint venture between Liberi Group (global leading L&BD consulting firm in Europe) and C Cube Lab (leading biotech business consulting firm in Korea). This JV was launched by combining the capabilities of both companies to enhance and maximize the performance of global licensing and co-development advisory services for Korean bio companies. We provide professional consulting services for implementing global licensing-out, co-development, and investment attraction, by combining Liberi Group’s extensive global L&BD success experience with C Cube Lab’s domestic and international expertise in business strategy, market research, and business deals in the bio sector.
|
C60
|
|
PARTNERING
|
Liflex Science Inc
|
We aim to develop an oligonucleotide cartilage regeneration injection targeting miR-204, a key factor in the development of degenerative arthritis. Specifically, we have identified a target pathogenic factor that not only prevents disease progression but also induces cartilage regeneration. Furthermore, we have identified a substance that effectively inhibits this pathogenic factor and are conducting efficacy and toxicity testing.
|
A60
|
|
NextRegenX
|
Live Cell Instrument Co., Ltd.
|
Cell Culture Support Systems
|
B25
|
|
KOREA LIFE SCIENCE
|
LONZA Bioscience
|
[LONZA] Cocoon, Nucleofector System [FRESENIUS KABI] LOVO&CUE System
|
C12
|
|
KOREA LIFE SCIENCE
|
M.TECH STS CO., LTD.
|
Protective & Infection-Prevention Products for Biohealth Worksites
|
G42
|
|
KOREA LIFE SCIENCE
|
MBD (Medical & Bio Decision)
|
ASFA Spotter Mini (Automated 3D Cell & ECM Dispenser)
|
C42
|
|
KOREA LAB Autumn
|
MDK
|
NIR & RAMAN Analyzer, Water Analyzer, Peristaltic & Syringe Pump, Smart Stirrer, Gas Volume and Flow Meter, Antimicrobial Keyboard & Mouse
|
H21
|
|
PARTNERING
|
MediciBIO
|
MediciBio’s next-generation LNP platform consists of systemic, local, and organ-targeted delivery systems. Systemic LNPs provide excellent gene delivery with repeat dosing, local LNPs reduce unnecessary systemic exposure to enhance safety, and organ-targeted LNPs use proprietary lipids for precise delivery to organs such as spleen and lungs. This differentiated technology is broadly applicable to next-generation genetic therapeutics, including mRNA treatments and vaccines. In RNA therapeutics, we are developing a mutation-selective ASO for Avellino corneal dystrophy, a rare disorder. This therapy selectively suppresses mutant TGFBI mRNA, demonstrating safety and efficacy, and its eye-drop formulation offers convenient administration with potential to become world’s first approved treatment
|
H60
|
|
PARTNERING
|
Medience Co
|
Poster 2 sheets, Products of Medience Co.
|
H60
|
KYUNGYON EXHIBITION CORP.